You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEthosuximide
Accession NumberDB00593  (APRD00318)
TypeSmall Molecule
GroupsApproved
DescriptionAn anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. [PubChem]
Structure
Thumb
Synonyms
(+-)-2-Ethyl-2-methylsuccinimide
(±)-2-ethyl-2-methylsuccinimide
2-ethyl-2-methylsuccinimide
2-Methyl-2-ethylsuccinimide
3-ethyl-3-methyl-2,5-pyrrolidinedione
3-Ethyl-3-methylsuccinimide
3-Methyl-3-ethylpyrrolidine-2,5-dione
3-Methyl-3-ethylsuccinimide
Aethosuximide
alpha-Ethyl-alpha-methylsuccinimide
alpha-Methyl-alpha-ethylsuccinimide
Atysmal
Ethosuximid
Ethosuximide
Ethosuximidum
Etosuximida
gamma-Ethyl-gamma-methyl-succinimide
gamma-Methyl-gamma-ethyl-succinimide
Thilopemal
γ-ethyl-γ-methyl-succinimide
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ethosuximidecapsule250 mg/1oralGreenstone LLC2000-09-22Not applicableUs
Zarontincapsule250 mg/1oralParke Davis Div Of Pfizer Inc2000-09-22Not applicableUs
Zarontin Cap 250mgcapsule250 mgoralErfa Canada 2012 Inc1960-12-31Not applicableCanada
Zarontin Syr 250mg/5mlsyrup250 mgoralErfa Canada 2012 Inc1964-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ethosuximidesolution250 mg/5mLoralVersa Pharm Incorporated2004-01-01Not applicableUs
Ethosuximidecapsule250 mg/1oralAvera Mc Kennan Hospital2015-10-30Not applicableUs
Ethosuximidesolution250 mg/5mLoralMikart, Inc.2003-12-22Not applicableUs
Ethosuximidecapsule250 mg/1oralVersa Pharm Incorporated2008-09-01Not applicableUs
Ethosuximidesolution250 mg/5mLoralTeva Pharmaceuticals USA Inc1994-07-01Not applicableUs
Ethosuximidecapsule250 mg/1oralPliva Inc.2002-11-01Not applicableUs
Ethosuximidecapsule250 1/1oralZydus Pharmaceuticals (USA) Inc.2012-10-10Not applicableUs
Ethosuximidesolution250 mg/5mLoralPharmaceutical Associates, Inc.2000-11-22Not applicableUs
Ethosuximidesolution250 mg/5mLoralGreenstone LLC2002-02-27Not applicableUs
Ethosuximidecapsule, liquid filled250 mg/1oralBanner Life Sciences Llc.2015-06-01Not applicableUs
Ethosuximidecapsule250 mg/1oralHeritage Pharmaceuticals Inc.2012-10-10Not applicableUs
Zarontinsolution250 mg/5mLoralParke Davis Div Of Pfizer Inc2002-02-27Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EmesideChemidex
EthymalApotex Europe
EtoxinApsen
PetimidOsel
PetinimidGerot
PetnidanDesitin
SuxilepJenapharm
SuxinutinMcNeil
ZarondanPfizer
Brand mixturesNot Available
SaltsNot Available
Categories
UNII5SEH9X1D1D
CAS number77-67-8
WeightAverage: 141.1677
Monoisotopic: 141.078978601
Chemical FormulaC7H11NO2
InChI KeyInChIKey=HAPOVYFOVVWLRS-UHFFFAOYSA-N
InChI
InChI=1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)
IUPAC Name
3-ethyl-3-methylpyrrolidine-2,5-dione
SMILES
CCC1(C)CC(=O)NC1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dicarboximides. These are carboxylic acid amides in which the two acyl groups linked to the central nitrogen atoms are carboacyl groups.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassCarboxylic acid derivatives
Direct ParentDicarboximides
Alternative Parents
Substituents
  • Dicarboximide
  • 2-pyrrolidone
  • Pyrrolidone
  • Pyrrolidine
  • Carboxylic acid imide, n-unsubstituted
  • Lactam
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of petit mal epilepsy.
PharmacodynamicsUsed in the treatment of epilepsy. Ethosuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of epileptiform attacks is reduced, apparently by depression of the motor cortex and elevation of the threshold of the central nervous system to convulsive stimuli.
Mechanism of actionBinds to T-type voltage sensitive calcium channels. Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the "low-voltage activated (LVA)" group and are strongly blocked by mibefradil. A particularity of this type of channels is an opening at quite negative potentials and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes.
Related Articles
AbsorptionBioavailability following oral administration is 93%.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic, via CYP3A4 and CYP2E1.

Route of eliminationNot Available
Half life53 hours
ClearanceNot Available
ToxicityAcute overdoses may produce nausea, vomiting, and CNS depression including coma with respiratory depression.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9983
Caco-2 permeable+0.5262
P-glycoprotein substrateNon-substrate0.5832
P-glycoprotein inhibitor INon-inhibitor0.7859
P-glycoprotein inhibitor IINon-inhibitor0.9923
Renal organic cation transporterNon-inhibitor0.8867
CYP450 2C9 substrateNon-substrate0.8492
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.5108
CYP450 1A2 substrateNon-inhibitor0.9242
CYP450 2C9 inhibitorNon-inhibitor0.9072
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9276
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.93
Ames testNon AMES toxic0.858
CarcinogenicityNon-carcinogens0.8526
BiodegradationNot ready biodegradable0.9299
Rat acute toxicity1.9213 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9939
hERG inhibition (predictor II)Non-inhibitor0.9795
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Banner pharmacaps inc
  • Convenant pharma inc
  • Parke davis div warner lambert co
  • Mikart inc
  • Pharmaceutical assoc inc div beach products
  • Teva pharmaceuticals usa
  • Parke davis pharmaceutical research div warner lambert co
Packagers
Dosage forms
FormRouteStrength
Capsuleoral250 1/1
Capsule, liquid filledoral250 mg/1
Capsuleoral250 mg/1
Solutionoral250 mg/5mL
Capsuleoral250 mg
Syruporal250 mg
Prices
Unit descriptionCostUnit
Ethosuximide 250 mg/5ml Solution 474ml Bottle84.2USD bottle
Ethosuximide 250 mg capsule1.26USD capsule
Zarontin 250 mg capsule1.16USD capsule
Zarontin 250 mg/5ml Solution0.34USD ml
Zarontin 50 mg/ml Syrup0.07USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point64.5 °CPhysProp
water solubility39.2 g/LNot Available
logP0.38ATKINSON,HC & BERG,EJ (1988)
Predicted Properties
PropertyValueSource
Water Solubility101.0 mg/mLALOGPS
logP0.1ALOGPS
logP0.55ChemAxon
logS-0.15ALOGPS
pKa (Strongest Acidic)10.73ChemAxon
pKa (Strongest Basic)-6.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.17 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity35.96 m3·mol-1ChemAxon
Polarizability14.45 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.34 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-08mi-9300000000-3d87944377ee1f85803dView in MoNA
References
Synthesis Reference

Miller, C.A. and Long, L.M.; U.S. Patent 2,993,835; July 25,1961; assigned to Parke, Davis and Company.

General References
  1. Patsalos PN: Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies. Epilepsia. 2005;46 Suppl 9:140-8. [PubMed:16302888 ]
  2. Coulter DA, Huguenard JR, Prince DA: Specific petit mal anticonvulsants reduce calcium currents in thalamic neurons. Neurosci Lett. 1989 Mar 13;98(1):74-8. [PubMed:2710401 ]
  3. Coulter DA, Huguenard JR, Prince DA: Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol. 1989 Jun;25(6):582-93. [PubMed:2545161 ]
  4. Coulter DA, Huguenard JR, Prince DA: Differential effects of petit mal anticonvulsants and convulsants on thalamic neurones: calcium current reduction. Br J Pharmacol. 1990 Aug;100(4):800-6. [PubMed:2169941 ]
  5. Kostyuk PG, Molokanova EA, Pronchuk NF, Savchenko AN, Verkhratsky AN: Different action of ethosuximide on low- and high-threshold calcium currents in rat sensory neurons. Neuroscience. 1992 Dec;51(4):755-8. [PubMed:1336826 ]
External Links
ATC CodesN03AD51N03AD01
AHFS Codes
  • 28:12.20
PDB EntriesNot Available
FDA labelDownload (174 KB)
MSDSDownload (73.5 KB)
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with 3,4-Methylenedioxymethamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Ethosuximide.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Ethosuximide.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Ethosuximide.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Ethosuximide.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Ethosuximide.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Ethosuximide.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Ethosuximide.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Ethosuximide.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ethosuximide.
AmiodaroneThe metabolism of Ethosuximide can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Ethosuximide.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ethosuximide.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ethosuximide.
AmoxapineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Ethosuximide.
AmphetamineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Amphetamine.
AprepitantThe serum concentration of Ethosuximide can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethosuximide.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Ethosuximide.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Ethosuximide.
AtazanavirThe metabolism of Ethosuximide can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Ethosuximide can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Ethosuximide.
AzelastineEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Ethosuximide.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Ethosuximide.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Ethosuximide.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Ethosuximide.
BenzphetamineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Ethosuximide.
BexaroteneThe serum concentration of Ethosuximide can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Ethosuximide can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Ethosuximide can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Ethosuximide can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
BrimonidineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ethosuximide.
BrompheniramineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Ethosuximide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ethosuximide.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Ethosuximide.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethosuximide.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ethosuximide.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Ethosuximide.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Ethosuximide.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Ethosuximide.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Ethosuximide.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ethosuximide.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ethosuximide.
CarbinoxamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Ethosuximide.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ethosuximide.
CeritinibThe serum concentration of Ethosuximide can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ethosuximide.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ethosuximide.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ethosuximide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Ethosuximide.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ethosuximide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Chlorphenamine.
ChlorphentermineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Chlorphentermine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ethosuximide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethosuximide.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ethosuximide.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ethosuximide.
CitalopramThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Citalopram.
ClarithromycinThe metabolism of Ethosuximide can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Ethosuximide can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Ethosuximide.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Ethosuximide.
ClomipramineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Ethosuximide.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethosuximide.
ClotrimazoleThe metabolism of Ethosuximide can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Ethosuximide.
CobicistatThe serum concentration of Ethosuximide can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Ethosuximide.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ethosuximide.
ConivaptanThe serum concentration of Ethosuximide can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Ethosuximide can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethosuximide.
CyclosporineThe metabolism of Ethosuximide can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ethosuximide.
Cyproterone acetateThe serum concentration of Ethosuximide can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Ethosuximide can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethosuximide.
DapoxetineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dapoxetine.
DarunavirThe metabolism of Ethosuximide can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Ethosuximide can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Ethosuximide can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Ethosuximide can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Ethosuximide.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Ethosuximide.
DesipramineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Ethosuximide.
DexamethasoneThe serum concentration of Ethosuximide can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethosuximide.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ethosuximide.
DextroamphetamineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Dextroamphetamine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ethosuximide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ethosuximide.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Ethosuximide.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ethosuximide.
DifenoxinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethosuximide.
DihydroergotamineThe metabolism of Ethosuximide can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ethosuximide.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ethosuximide.
DiltiazemThe metabolism of Ethosuximide can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethosuximide.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethosuximide.
DisulfiramThe metabolism of Ethosuximide can be decreased when combined with Disulfiram.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Ethosuximide.
DoxepinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Doxepin.
DoxycyclineThe metabolism of Ethosuximide can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
DoxylamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Ethosuximide.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
DronedaroneThe metabolism of Ethosuximide can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Ethosuximide.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Ethosuximide.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ethosuximide.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Ethosuximide.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Ethosuximide.
EfavirenzThe serum concentration of Ethosuximide can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Ethosuximide.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Ethosuximide.
EnzalutamideThe serum concentration of Ethosuximide can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Ethosuximide can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Ethosuximide can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ethosuximide.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ethosuximide.
EthanolEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Ethosuximide.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ethosuximide.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ethosuximide.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ethosuximide.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Ethosuximide.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Ethosuximide.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Ethosuximide.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethosuximide.
EtoperidoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Ethosuximide.
EtravirineThe serum concentration of Ethosuximide can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ethosuximide.
FenfluramineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethosuximide.
FexofenadineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Flibanserin.
FluconazoleThe metabolism of Ethosuximide can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ethosuximide.
FlunarizineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ethosuximide.
FluoxetineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethosuximide.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethosuximide.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ethosuximide.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ethosuximide.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Ethosuximide.
FluvoxamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fluvoxamine.
FluvoxamineThe metabolism of Ethosuximide can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Ethosuximide can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Ethosuximide can be increased when it is combined with Fosaprepitant.
FosphenytoinEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Ethosuximide.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Ethosuximide.
Fusidic AcidThe serum concentration of Ethosuximide can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethosuximide.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Ethosuximide is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ethosuximide.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Ethosuximide.
GuanfacineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Ethosuximide.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ethosuximide.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Ethosuximide.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Ethosuximide.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ethosuximide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ethosuximide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethosuximide.
Hydroxyamphetamine hydrobromideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
HydroxyzineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Hydroxyzine.
IdelalisibThe serum concentration of Ethosuximide can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Iloperidone.
ImatinibThe metabolism of Ethosuximide can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ethosuximide.
IndalpineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Indalpine.
IndinavirThe metabolism of Ethosuximide can be decreased when combined with Indinavir.
IsavuconazoniumThe metabolism of Ethosuximide can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Ethosuximide.
IsoniazidThe metabolism of Ethosuximide can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Ethosuximide can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Ethosuximide can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Ethosuximide can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethosuximide.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ethosuximide.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ethosuximide.
KetoconazoleThe metabolism of Ethosuximide can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ethosuximide.
LevetiracetamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Ethosuximide.
LevocabastineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ethosuximide.
LevomilnacipranThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ethosuximide.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ethosuximide.
LisdexamfetamineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Lisdexamfetamine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Ethosuximide.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Ethosuximide.
LopinavirThe metabolism of Ethosuximide can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Ethosuximide.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ethosuximide.
LovastatinThe metabolism of Ethosuximide can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ethosuximide.
Lu AA21004The risk or severity of adverse effects can be increased when Ethosuximide is combined with Lu AA21004.
LuliconazoleThe serum concentration of Ethosuximide can be increased when it is combined with Luliconazole.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ethosuximide.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Ethosuximide.
MefloquineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Ethosuximide.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Ethosuximide.
MephentermineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ethosuximide.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethosuximide.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ethosuximide.
MetaxaloneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ethosuximide.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Ethosuximide.
MethamphetamineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Ethosuximide.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Ethosuximide.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ethosuximide.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Ethosuximide.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Ethosuximide.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ethosuximide.
MethsuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ethosuximide.
MetyrosineEthosuximide may increase the sedative activities of Metyrosine.
MianserinThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Mianserin.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethosuximide.
MifepristoneThe metabolism of Ethosuximide can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
MirtazapineEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ethosuximide.
MitotaneThe serum concentration of Ethosuximide can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Ethosuximide can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Ethosuximide.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ethosuximide.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
NabiloneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Nabilone.
NafcillinThe serum concentration of Ethosuximide can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ethosuximide.
NefazodoneThe metabolism of Ethosuximide can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Ethosuximide can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Ethosuximide can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Ethosuximide can be decreased when combined with Nevirapine.
NicotineThe metabolism of Ethosuximide can be decreased when combined with Nicotine.
NilotinibThe metabolism of Ethosuximide can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ethosuximide.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Ethosuximide.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Ethosuximide.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ethosuximide.
OlanzapineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Olanzapine.
OlaparibThe metabolism of Ethosuximide can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ethosuximide.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Ethosuximide.
OrlistatThe serum concentration of Ethosuximide can be decreased when it is combined with Orlistat.
OrphenadrineEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Ethosuximide.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Ethosuximide.
OsimertinibThe serum concentration of Ethosuximide can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ethosuximide.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ethosuximide.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ethosuximide.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethosuximide.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethosuximide.
PalbociclibThe serum concentration of Ethosuximide can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethosuximide.
ParaldehydeEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Ethosuximide.
ParoxetineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethosuximide.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ethosuximide.
PerampanelThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Ethosuximide.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ethosuximide.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ethosuximide.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ethosuximide.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Ethosuximide.
PhentermineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Phentermine.
PhenytoinEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Ethosuximide.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ethosuximide.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Ethosuximide.
PipotiazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pomalidomide.
PosaconazoleThe metabolism of Ethosuximide can be decreased when combined with Posaconazole.
PramipexoleEthosuximide may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Ethosuximide.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Ethosuximide.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ethosuximide.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Ethosuximide.
PrimidoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Ethosuximide.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethosuximide.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Ethosuximide.
PromethazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ethosuximide.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Ethosuximide.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Ethosuximide.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ethosuximide.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Ethosuximide.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Ethosuximide.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethosuximide.
RamelteonThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ramelteon.
RanolazineThe metabolism of Ethosuximide can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethosuximide.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ethosuximide.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ethosuximide.
RifabutinThe metabolism of Ethosuximide can be increased when combined with Rifabutin.
RifampicinThe metabolism of Ethosuximide can be increased when combined with Rifampicin.
RifapentineThe metabolism of Ethosuximide can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethosuximide.
RitonavirThe metabolism of Ethosuximide can be decreased when combined with Ritonavir.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Ethosuximide.
RopiniroleEthosuximide may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethosuximide.
RotigotineEthosuximide may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ethosuximide.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Ethosuximide.
SaquinavirThe metabolism of Ethosuximide can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethosuximide.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Ethosuximide.
SertralineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethosuximide.
SildenafilThe metabolism of Ethosuximide can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Ethosuximide can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Ethosuximide can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Ethosuximide.
St. John's WortThe serum concentration of Ethosuximide can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethosuximide.
SulfisoxazoleThe metabolism of Ethosuximide can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethosuximide.
SuvorexantThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tasimelteon.
TelaprevirThe metabolism of Ethosuximide can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Ethosuximide can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ethosuximide.
TetrabenazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Ethosuximide.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Ethosuximide.
ThalidomideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Ethosuximide.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ethosuximide.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Ethosuximide.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ethosuximide.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ethosuximide.
TiagabineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tiagabine.
TiclopidineThe metabolism of Ethosuximide can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Ethosuximide.
TizanidineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tizanidine.
TocilizumabThe serum concentration of Ethosuximide can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ethosuximide.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Ethosuximide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethosuximide.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ethosuximide.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethosuximide.
TrazodoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ethosuximide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethosuximide.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ethosuximide.
TrimipramineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Ethosuximide.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Ethosuximide.
VenlafaxineThe metabolism of Ethosuximide can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Ethosuximide can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Vilazodone.
VoriconazoleThe metabolism of Ethosuximide can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Ethosuximide.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ethosuximide.
ZiconotideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Zimelidine.
ZiprasidoneThe metabolism of Ethosuximide can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Ethosuximide.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Ethosuximide.
ZonisamideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Ethosuximide.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Ethosuximide.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ethosuximide.
Food Interactions
  • Avoid alcohol.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the "low-v...
Gene Name:
CACNA1G
Uniprot ID:
O43497
Molecular Weight:
262468.62 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Gomora JC, Daud AN, Weiergraber M, Perez-Reyes E: Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32. [PubMed:11641441 ]
  3. Wang G, Thompson SM: Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions. J Neurosci. 2008 Nov 12;28(46):11959-69. doi: 10.1523/JNEUROSCI.3296-08.2008. [PubMed:19005061 ]
  4. Matthews EA, Dickenson AH: Effects of ethosuximide, a T-type Ca(2+) channel blocker, on dorsal horn neuronal responses in rats. Eur J Pharmacol. 2001 Mar;415(2-3):141-9. [PubMed:11274992 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Monooxygenase activity
Specific Function:
Exhibits low testosterone 6-beta-hydroxylase activity.
Gene Name:
CYP3A43
Uniprot ID:
Q9HB55
Molecular Weight:
57669.21 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23